SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
1. SPEAR Study Group recommends studying VYD2311 for Long COVID treatment. 2. Long-term high-neutralizing antibody deployment is vital in proposed clinical trial. 3. VYD2311 aims to address viral persistence in Long COVID patients. 4. Clinical study is backed by NIH initiative RECOVER-TLC for funding. 5. Positive presentations scheduled for September 2025 may boost investor confidence.